Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,410 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02848001 | A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes | terminated | Phase 1 | 101 | CelgeneINDUSTRY | 6 | Jun 12, 2025 | clinicaltrials |
| NCT04971733 | A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease | completed | Phase 1 / Phase 2 | 8 | Eisai Inc.INDUSTRY | 2 | Jun 10, 2025 |
| clinicaltrials |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 141 | AmgenINDUSTRY | 33 | Jun 4, 2025 | clinicaltrials |
| NCT06603844 | First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | recruiting | Phase 1 / Phase 2 | 156 | Corbus Pharmaceuticals Inc.INDUSTRY | 2 | Jun 3, 2025 | clinicaltrials |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW) | completed | Phase 1 / Phase 2 | 590 | Hoffmann-La RocheINDUSTRY | 13 | May 31, 2025 | clinicaltrials |
| NCT02953509 | Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 178 | Gilead SciencesINDUSTRY | 3 | May 29, 2025 | clinicaltrials |
| NCT04393298 | A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 93 | UCB Biopharma SRLINDUSTRY | 2 | May 29, 2025 | clinicaltrials |
| NCT04972981 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors | completed | Phase 1 | 30 | ADC Therapeutics S.A.INDUSTRY | 3 | May 22, 2025 | clinicaltrials |
| NCT05389462 | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | terminated | Phase 1 | 128 | ADC Therapeutics S.A.INDUSTRY | 4 | May 22, 2025 | clinicaltrials |
| NCT03066648 | Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | completed | Phase 1 | 241 | Novartis PharmaceuticalsINDUSTRY | 8 | May 18, 2025 | clinicaltrials |
| NCT03673787 | A Trial of Ipatasertib in Combination With Atezolizumab(IceCAP) | active not recruiting | Phase 1 / Phase 2 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT04075396 | A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 29 | Janssen Research & Development, LLCINDUSTRY | 3 | Apr 29, 2025 | clinicaltrials |
| NCT00794131 | Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors | completed | Phase 1 | 43 | Genelux GmbHINDUSTRY | 1 | Apr 24, 2025 | clinicaltrials |
| NCT03260322 | A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | completed | Phase 1 | 169 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Apr 24, 2025 | clinicaltrials |
| NCT03428958 | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | completed | Phase 1 / Phase 2 | 111 | NuCana plcOTHER | 3 | Apr 23, 2025 | clinicaltrials |
| NCT02875223 | A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas | terminated | Phase 1 | 75 | CelgeneINDUSTRY | 5 | Apr 20, 2025 | clinicaltrials |
| NCT00516724 | Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel | completed | Phase 1 | 189 | AstraZenecaINDUSTRY | 3 | Apr 11, 2025 | clinicaltrials |
| NCT02735083 | A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19 | active not recruiting | Phase 1 | 28 | Institut de Recherches Internationales ServierOTHER | 5 | Apr 11, 2025 | clinicaltrials |
| NCT04630756 | AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer | completed | Phase 1 / Phase 2 | 40 | AstraZenecaINDUSTRY | 9 | Apr 9, 2025 | clinicaltrials |
| NCT04556617 | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | terminated | Phase 1 / Phase 2 | 19 | Opna Bio LLCINDUSTRY | 2 | Apr 8, 2025 | clinicaltrials |
| NCT04166721 | WaKING: Wnt and checKpoint INhibition in Gastric Cancer | active not recruiting | Phase 1 / Phase 2 | 52 | Royal Marsden NHS Foundation TrustOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04236414 | Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours | completed | Phase 1 | 16 | AstraZenecaINDUSTRY | 6 | Apr 4, 2025 | clinicaltrials |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | completed | Phase 1 | 269 | ExelixisINDUSTRY | 9 | Apr 4, 2025 | clinicaltrials |
| NCT04758767 | CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 10 | CASI pharmaceuticals, Inc.INDUSTRY | 2 | Apr 3, 2025 | clinicaltrials |
| NCT03733990 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | completed | Phase 1 / Phase 2 | 216 | Faron Pharmaceuticals LtdINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 407 | Taiho Oncology, Inc.INDUSTRY | 13 | Mar 27, 2025 | clinicaltrials |
| NCT04830592 | A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck(MOAT) | completed | Phase 1 | 36 | Akamis BioINDUSTRY | 1 | Mar 24, 2025 | clinicaltrials |
| NCT05043714 | Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours(NEBULA) | completed | Phase 1 | 30 | Akamis BioINDUSTRY | 2 | Mar 24, 2025 | clinicaltrials |
| NCT04382898 | PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)(PRO-MERIT) | terminated | Phase 1 / Phase 2 | 75 | BioNTech SEINDUSTRY | 4 | Mar 20, 2025 | clinicaltrials |
| NCT04990479 | Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma | terminated | Phase 1 | 7 | Nouscom SRLINDUSTRY | 3 | Mar 20, 2025 | clinicaltrials |
| NCT04101357 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | terminated | Phase 1 / Phase 2 | 54 | BioNTech SEINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT02098343 | p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | completed | Phase 1 / Phase 2 | 247 | Aprea TherapeuticsINDUSTRY | 8 | Mar 17, 2025 | clinicaltrials |
| NCT04761198 | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors | completed | Phase 1 / Phase 2 | 76 | Mereo BioPharmaINDUSTRY | 2 | Mar 17, 2025 | clinicaltrials |
| NCT02716012 | First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer(OUTREACH) | unknown | Phase 1 | 75 | Mina Alpha LimitedINDUSTRY | 3 | Mar 10, 2025 | clinicaltrials |
| NCT04032847 | ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC | terminated | Phase 1 / Phase 2 | 27 | Achilles Therapeutics UK LimitedINDUSTRY | 5 | Mar 10, 2025 | clinicaltrials |
| NCT03997474 | ATL001 in Patients With Metastatic or Recurrent Melanoma | terminated | Phase 1 / Phase 2 | 13 | Achilles Therapeutics UK LimitedINDUSTRY | 2 | Mar 7, 2025 | clinicaltrials |
| NCT03397654 | Study of Pembrolizumab Following TACE in Primary Liver Carcinoma(PETAL) | completed | Phase 1 / Phase 2 | 26 | Imperial College LondonOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT04105335 | A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)(TIMEPOINT) | completed | Phase 1 | 50 | Mina Alpha LimitedINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT05441501 | A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer | completed | Phase 1 | 39 | Janssen Research & Development, LLCINDUSTRY | 2 | Mar 4, 2025 | clinicaltrials |
| NCT03250676 | Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer | completed | Phase 1 / Phase 2 | 151 | Eisai Inc.INDUSTRY | 3 | Feb 25, 2025 | clinicaltrials |
| NCT04718675 | A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) | terminated | Phase 1 / Phase 2 | 135 | Kronos BioINDUSTRY | 3 | Feb 17, 2025 | clinicaltrials |
| NCT03593226 | Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour | completed | Phase 1 / Phase 2 | 38 | Agalimmune Ltd.INDUSTRY | 3 | Feb 14, 2025 | clinicaltrials |
| NCT04041050 | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | active not recruiting | Phase 1 | 85 | AbbVieINDUSTRY | 14 | Feb 14, 2025 | clinicaltrials |
| NCT05104515 | First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | recruiting | Phase 1 | 36 | Oxford Vacmedix UK Ltd.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT01346540 | A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology. | completed | Phase 1 | 16 | Boehringer IngelheimINDUSTRY | 4 | Feb 12, 2025 | clinicaltrials |
| NCT00950742 | Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer. | completed | Phase 1 | 18 | Boehringer IngelheimINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | terminated | Phase 1 | 133 | Seagen Inc.INDUSTRY | 6 | Feb 10, 2025 | clinicaltrials |
| NCT04862780 | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | terminated | Phase 1 | 177 | Blueprint Medicines CorporationINDUSTRY | 10 | Feb 10, 2025 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials